Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Nidhi GuptaDharna GuptaJyoti DixitNikita MehraAshish SinghManjunath Nookala KrishnamurthySushmita GhoshalKavitha RajsekharJayachandran Perumal KalaiyarasiPartha Sarathi RoyPrabhat Singh MalikAnisha MathewPankaj MalhotraSudeep GuptaLalit KumarAmal KatakiShankar PrinjaPublished in: Applied health economics and health policy (2022)
CDK4/6i (ribociclib and palbociclib) therapy is not a cost-effective treatment option for MBC patients. A 72% reduction in the reimbursement rate for fulvestrant monotherapy will make it a cost-effective treatment option in the Indian context.